Valuation: PolyPid Ltd.

Market Cap 105M 93.66M 87.42M 79.68M 150M 10.13B 152M 1.06B 410M 5.18B 396M 387M 16.63B P/E 2026 *
-5.83x
P/E 2027 * -4.23x
Enterprise Value 105M 93.66M 87.42M 79.68M 150M 10.13B 152M 1.06B 410M 5.18B 396M 387M 16.63B EV / Sales 2026 *
7.03x
EV / Sales 2027 * 12.2x
Free-Float
87.66%
Yield 2026 *
-
Yield 2027 * -
1 day-3.35%
1 week-0.57%
Current month-1.52%
1 month-1.52%
3 months+3.39%
6 months+18.22%
Current year+19.59%
1 week 5.06
Extreme 5.06
5.55
1 month 5
Extreme 5
5.56
Current year 3.65
Extreme 3.65
5.73
1 year 3.06
Extreme 3.06
5.73
3 years 2.3
Extreme 2.3
9.2
5 years 2.3
Extreme 2.3
257.1
10 years 2.3
Extreme 2.3
583.5
Manager TitleAgeSince
Chief Executive Officer 52 2022-06-30
Director of Finance/CFO 39 -
Chief Tech/Sci/R&D Officer 61 2025-08-17
Director TitleAgeSince
Director/Board Member 84 2008-03-31
Director/Board Member 52 2022-08-07
Director/Board Member 74 2018-11-30
Date Insider Type Main position Quantity % Market Cap. Importance
7/15/26 Free

Director

9,132 0.0896%
7/15/26 Free

Director

9,132 0.0896%
7/15/26 Free

Chairman

9,132 0.0896%
Change 5-day change 1-year change 3-year change Capi.($)
-3.35%-0.57%+48.29%+21.55% 105M
-0.61%-3.43%+36.07%+117.61% 1,019B
-1.02%-5.60%+35.72%+64.82% 617B
+1.11%-0.58%+12.36%+78.27% 464B
+0.34%-3.01%+61.79%+41.79% 356B
-0.95%-4.05%+20.54%+40.33% 333B
-1.46%-2.89%+10.57%+26.54% 267B
-1.35%-5.43%-6.17%+8.82% 244B
-1.04%-2.79%+35.30%+54.42% 218B
-1.87%-4.10%+28.44%+97.54% 179B
Average -1.02%-3.11%+28.29%+55.17% 369.73B
Weighted average by Cap. -0.60%-3.33%+29.07%+71.15%

Financials

2026 *2027 *
Net sales 15M 13.33M 12.44M 11.34M 21.38M 1.44B 21.58M 151M 58.33M 737M 56.32M 55.1M 2.37B 8.68M 7.71M 7.19M 6.56M 12.37M 834M 12.48M 87.06M 33.74M 426M 32.57M 31.86M 1.37B
Net income -20.03M -17.79M -16.61M -15.14M -28.55M -1.93B -28.81M -201M -77.88M -984M -75.19M -73.56M -3.16B -31.55M -28.03M -26.16M -23.85M -44.98M -3.03B -45.39M -317M -123M -1.55B -118M -116M -4.98B
Net Debt - -
Logo PolyPid Ltd.
Polypid Ltd is a biopharmaceutical company at the clinical stage, based in Israel . The company focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines.
Employees
72
Date Price Change Volume
26-10-02 US$5.190 -3.35% 168,309
26-10-01 US$5.370 +1.90% 118,780
26-09-30 US$5.270 -0.38% 47,391
26-09-29 US$5.290 -0.38% 66,038
26-09-28 US$5.310 +1.72% 75,998
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
5.190USD
Average target price
11.75USD
Spread / Average Target
+126.40%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PYPD Stock